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Background
Moderate-to-severe allergic rhinitis (AR) is often poorly
controlled. Patients remain symptomatic on treatment,
despite multiple therapies. A more effective treatment is
needed. We assessed the efficacy of MP29-02* (a novel
intranasal formulation of azelastine hydrochloride (AZE)
and fluticasone propionate (FP) in an advanced delivery
system) during different seasons and for different symp-
toms and severities vs AZE, FP or placebo (PLA).
Method
Four thousand and twenty two moderate/severe SAR
patients (≥12 yrs) were randomized into 4 double-blind,
PLA-controlled, 14-day, parallel-group trials to MP29-02*,
AZE, FP or PLA nasal sprays (1 spray/nostril bid), during
the Texas mountain cedar (MP4001), Spring (MP4002),
Autumn (MP4004) and Spring/Summer (MP4006) sea-
sons. Overall change from baseline (CFB) in reflective
total nasal symptom score (rTNSS) was the primary end-
point. It was assessed by severity post-hoc in 2 ways (more
severe AR: median baseline rTNSS >18.9 or median base-
line RQLQ >3.9; less severe AR: median baseline rTNSS
≤18.9 or median baseline RQLQ ≤ 3.9). CFB in individual
nasal and ocular symptom scores was also assessed.
Results
The response to MP29-02* was consistent across seasons;
mean CFB -5.5, -5.5, -5.6 and -5.6 in each study (p<0.001
vs PLA). Nasal symptom relief was significantly greater
with MP29-02* than with FP or AZE in all studies. In
study MP4001 MP29-02 was approx. twice as effective as
FP (relative difference (RD) 47%; p=0.0031) and 3 times as
effective as AZE (RD: 66%; p<0.0001). For less severe AR
(defined by median baseline rTNSS) the RD to MP29-02*
was 42% vs FP (p=0.0188) and 64% vs AZE (p=0.0002),
increasing to 49% and 70% vs FP (p=0.0436) and AZE
(p=0.0035), respectively for more severe AR. When sever-
ity was categorized according to median baseline RQLQ
the RD to MP29-02* was 60% vs FP (p=0.0244) and 69%
vs AZE (p=0.0068) for those with less severe AR compared
to 49% vs FP (p=0.0194) and 64% vs AZE (p=0.0013) for
those with more severe AR. MP29-02* provided superior
relief from all nasal and ocular symptoms than AZE or FP,
which was particularly evident for congestion (p=0.0034 vs
FP; p=0.0001 vs AZE) & ocular itching (p=0.0240 vs FP;
p=0.0033 vs AZE).
Conclusion
MP29-02* provides consistently superior symptomatic
relief to an intranasal antihistamine or topical corticoster-
oid in AR patients regardless of season, symptom or sever-
ity, supporting MP29-02 as the drug of choice for AR.
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